DOLPHIN-VIVO: Diagnosis Of LymPHoma IN Vivo (In Vivo Phase)
NCT ID: NCT05010369
Last Updated: 2025-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
14 participants
INTERVENTIONAL
2024-09-02
2025-06-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The investigators have already shown that it is possible to tell the difference between healthy and diseased tissue in the laboratory by looking at the light emitted by tissue when a low power laser is shone on to it. The investigators intend to use this technique, known as "Raman Spectroscopy" (RS) to tell if tissue in the node is cancerous or healthy. By combining RS with a fine needle, the technique can target tissues below the skin with minimal invasion. Our needle will provide the clinician with instant diagnosis without the delay and cost of a laboratory analysis by pathologists.
The investigators have designed a probe that slides through a fine needle, guided by ultrasound, to the lymph node. The space between the two needles provides space for cell aspirate.
The investigators propose to measure spectra from excess lymph node biopsy samples taken during standard routine diagnostic biopsy.
The investigators are also interested to see if they can successfully extract a fine needle aspiration (FNA) biopsy sample using the device, as well as record a RS measurement. If successful this would ease clinical adoption as the study could run in parallel with existing standard routine clinical practice, using just one device.
This study will evaluate the new device on half a lymph node that will be excised and snap-frozen during a routine surgical biopsy, to gather data for submission of approvals for an in-vivo study to follow.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Analysis of Molecular Markers of Drug Resistance in Tumor Biopsies From Previously Untreated Aggressive Non-Hodgkin's Lymphoma
NCT00026910
Clinical Application of Liquid Biopsy for Precise Diagnosis and Prognosis in Lymphoma
NCT04062877
SWOG-8819 Collecting, Analyzing, and Storing Tissue Samples From Patients With Non-Hodgkin's Lymphoma
NCT00900484
Tissue Collection for Studies of Lymph Cancer
NCT01676805
A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer
NCT05708599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The project will develop a combined FNA/Raman spectroscopy needle probe. This study will evaluate this device on excised lymph node tissue to gather data for submission of approvals for an in-vivo study to follow. Raman \& FTIR (fourier transform infrared) spectra will be correlated with routine histopathology results using multivariate analysis methods. Cytology samples taken using the device will be compared with histopathology results.
Aims
To demonstrate that the FNA/Raman spectroscopy probe device, developed as part of this project, can:
Safely perform measurement of Raman spectra on excised lymph node tissue Safely perform FNA (fine needle aspiration) biopsies on excised lymph node tissue To evaluate the performance of a Raman needle probe to detect lymphoma \& malignancy in excised head \& neck lymph nodes and differentiate from benign nodes.
To develop the investigators understanding of vibrational spectroscopy signal characteristics in head \& neck lymph nodes (through Raman \& FTIR mapping measurements of tissue sections).
Objectives To test a new combined FNA and spectroscopic device on ex vivo tissue in preparation for an in vivo study.
Outcome
Primary Outcome Measures The FNA/Raman spectroscopy probe device can be used safely on excised lymph nodes to measure tissue spectra and collect FNA biopsies.
Diagnostic performance of vibrational spectroscopy for differentiation of lymphoma \& malignant nodes from benign nodes.
Secondary Outcome Measures Evaluation of the performance of a Raman needle probe to detect lymphoma \& malignancy in excised head \& neck lymph nodes and differentiate from benign nodes. To develop the investigators understanding of vibrational spectroscopy signal characteristics in head \& neck lymph nodes (through Raman \& FTIR mapping measurements of tissue sections).
Evaluation of the performance of a Raman needle probe to measure head \& neck lymph nodes (ergonomic design, ease of use etc.).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
DEVICE_FEASIBILITY
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
non-hodgkin lymphoma
patients diagnosed with non-hodgkin lymphoma
spectroscopic measurement
measurement of the tissue with spectroscopy
FNA biopsy
a fine needle aspiration (FNA) biopsy will be taken
histopathology and cytology
Histopathology and cytology will be performed on the samples
hodgkin lymphoma
patients diagnosed with hodgkin lymphoma
spectroscopic measurement
measurement of the tissue with spectroscopy
FNA biopsy
a fine needle aspiration (FNA) biopsy will be taken
histopathology and cytology
Histopathology and cytology will be performed on the samples
squamous cell carcinoma
patients diagnosed with squamous cell carcinoma
spectroscopic measurement
measurement of the tissue with spectroscopy
FNA biopsy
a fine needle aspiration (FNA) biopsy will be taken
histopathology and cytology
Histopathology and cytology will be performed on the samples
reactive
patients diagnosed with a reactive (non-cancerous) lymph node
spectroscopic measurement
measurement of the tissue with spectroscopy
FNA biopsy
a fine needle aspiration (FNA) biopsy will be taken
histopathology and cytology
Histopathology and cytology will be performed on the samples
other
none of the above. Other cancer and non-cancer conditions
spectroscopic measurement
measurement of the tissue with spectroscopy
FNA biopsy
a fine needle aspiration (FNA) biopsy will be taken
histopathology and cytology
Histopathology and cytology will be performed on the samples
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
spectroscopic measurement
measurement of the tissue with spectroscopy
FNA biopsy
a fine needle aspiration (FNA) biopsy will be taken
histopathology and cytology
Histopathology and cytology will be performed on the samples
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients undergoing lymphadenectomy as part of routine treatment
Exclusion Criteria
* Patients unable to consent to the study due to communication difficulties
* Patients unable to consent to the study due to lack of capacity
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gloucestershire Hospitals NHS Foundation Trust
OTHER
University of Bristol
OTHER
University of Exeter
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nick Stone
Role: PRINCIPAL_INVESTIGATOR
University of Exeter
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gloucestershire Hospitals NHS Foundation Trust
Gloucester, Gloucestershire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
272392
Identifier Type: REGISTRY
Identifier Source: secondary_id
II-LB-1117-20002
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
1819/31-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.